FDA warns of increased risk for heart-related issues, cancer linked to Xeljanz

The FDA has issued a safety alert warning patients and health providers of an increased risk for serious health-related problems and cancer linked to tofacitinib compared with TNF inhibitors among older patients.As part of the alert, the FDA has recommended that health care professionals consider the benefits and risks associated with tofacitinib (Xeljanz, Pfizer) when making treatment decisions for patients with rheumatoid arthritis or ulcerative colitis. Physicians should continue to follow the recommendations included in the drug’s prescribing information.However, patients shouldRead More